Furthermore, co-treatment using a PPARα agonist with Met has been shown to induce better therapeutic effects in various clinical studies for patients with T2DM [22] and for patients with non-alcoholic fatty liver disease (NAFLD) [23] in addition to an in vivo study using an advanced nonalcoholic steatohepatitis (NASH) rodent model [24]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.